RT Journal Article
SR Electronic
T1 Stratification of COVID-19 severity using SeptiCyte RAPID, a novel host immune response test
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.15.22279735
DO 10.1101/2022.09.15.22279735
A1 Victor Gravrand
A1 François Mellot
A1 Felix Ackermann
A1 Marie-Christine Ballester
A1 Benjamin Zuber
A1 James T. Kirk
A1 Krupa Navalkar
A1 Thomas D. Yager
A1 Fabien Petit
A1 Tiffany Pascreau
A1 Eric Farfour
A1 Marc Vasse
YR 2022
UL http://medrxiv.org/content/early/2022/09/18/2022.09.15.22279735.abstract
AB SeptiCyte® RAPID is a gene expression assay measuring the relative expression levels of host response genes PLA2G7 and PLAC8, indicative of a dysregulated immune response during sepsis. As severe forms of COVID-19 may be considered viral sepsis, we evaluated SeptiCyte RAPID in a series of 94 patients admitted to Foch Hospital (Suresnes, France) with proven SARS-CoV-2 infection. EDTA blood was collected prospectively in the emergency department (ED) in 67 cases, in the intensive care unit (ICU) in 23 cases and in conventional units in 4 cases. SeptiScore (0-15 scale) increased with COVID-19 severity. Patients in ICU had the highest SeptiScores, producing values comparable to 8 patients with culture-confirmed bacterial sepsis. Receiver operating characteristic (ROC) curve analysis had an area under the curve (AUC) of 0.81 for discriminating patients requiring ICU admission from patients who were immediately discharged or from patients requiring hospitalization in conventional units. SeptiScores increased with the extent of the lung injury. For 68 patients, a chest computed tomography (CT) scan was performed within 24 hours of COVID-19 diagnosis. SeptiScore > 7 suggested lung injury ≥ 50 % (AUC = 0.86). SeptiCyte RAPID was compared to other biomarkers for discriminating Critical + Severe COVID-19 in ICU, versus Moderate + Mild COVID-19 not in ICU. The mean AUC for SeptiCyte RAPID was superior to that of any individual biomarker or combination thereof. In contrast to C-reactive protein (CRP), correlation of SeptiScore with lung injury was not impacted by treatment with anti-inflammatory agents. SeptiCyte RAPID can be a useful tool to identify patients with severe forms of COVID-19 in ED, as well as during follow-up.Competing Interest StatementTDY, KN, JTK are current or former employees and shareholders in Immunexpress. The other authors declare no competing interests.Funding StatementThis study has been supported in part by contract # 75A50120C00125 from the DRIVe Solving Sepsis program of the Biomedical Advanced Research and Development Authority (BARDA), part of the US HHS Office of the Assistant Secretary for Preparedness and Response.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted under a blanket protocol for COVID-related research at the Foch Hospital (Information reutilisation des donnees personnelles et des echantillons biologiques a des fins de recherche V2 - 9 avril 2020), which had been established and approved by the local ethics committee of the Foch Hospital (IRB00012437). The study was performed in agreement with French ethical laws, such that the patients and their families were informed that their biological samples and data used for routine care could be used in an anonymous manner unless they expressed their opposition. No patients enrolled in this study, or their families, expressed opposition to the use of their biological samples and data, which according to the French ethical laws and Foch Hospital ethics committee constitutes informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsAHTarterial hypertensionARDSacute respiratory distress syndromeAUCarea under ROC curveCD16Fc receptor with low affinity for IgG, encoded by genes FCGR3A and FCGR3BBMIbody mass indexCIconfidence intervalCOVID-19coronavirus disease 2019CRPC-reactive proteinCTcomputed tomographyECMOextracorporeal membrane oxygenationEDEmergency DepartmentEDTAethylene diamine tetraacetic acidFfemaleGGOground glass opacityICUIntensive Care UnitMmaleNIHUnited States National Institutes of HealthNGSnext-generation sequencingNAnot availablePCTprocalcitoninPLA2G7Phospholipase A2 Group VII genePLAC8Placenta Associated 8 geneROCreceiver operating characteristic [curve]RT-qPCRreverse transcription - quantitative polymerase chain reactionSARS-CoV-2severe acute respiratory syndrome coronavirus 2SPCsample processing controlWHOWorld Health Organization